Supports advanced PhD students conducting innovative research to improve drug delivery, formulation, and performance for better clinical outcomes.
Funder: PhRMA Foundation
Due Dates: April 15, 2026 (Letter of Intent) | August 26, 2026 (Full application, by invitation)
Funding Amounts: $30,000/year for up to 2 years; stipend only, with up to $1,000/year for research-related incidentals or U.S. conference travel
Summary: Supports advanced PhD candidates conducting innovative research to optimize drug delivery, formulation, and performance for improved clinical outcomes.
Key Information: Two-step process: LOI required; only invited applicants may submit full applications.
This fellowship supports promising PhD students engaged in advanced thesis research focused on drug delivery, including pharmaceutics, biopharmaceutics, pharmaceutical technology, biotechnology, and biomedical engineering. The program aims to fund innovative, therapeutically relevant research that advances drug composition, dosage, and delivery methods to improve clinical outcomes, safety, and patient manageability. Eligible projects may address formulation composition, delivery technologies, CMC process development for challenging entities, and predictive modeling (including machine and deep learning) to correlate in vitro and in vivo drug performance. Proposals must clearly articulate the therapeutic payload, target tissue, dosing rationale, PK/PD feasibility, and, where applicable, translational validation and robust methodology. Proposals focused solely on platform development without a clear therapeutic application or feasibility path are not considered.